Prediction and prevention of sudden cardiac death in heart failure

The definition of sudden cardiac death (SCD) remains controversial. Many such deaths are not witnessed, and without cardiac monitoring at the time of death the assumption of an underlying arrhythmic cause is speculative. Nevertheless, it has been estimated that SCD accounts for 300 000 to 400 000 deaths annually in the USA.1 The degeneration of monomorphic ventricular tachycardia (VT) into ventricular fibrillation (VF) accounts for the majority of sudden arrhythmic deaths.w1 Despite considerable advances in the treatment of heart failure over the past 20 years, morbidity and mortality remain high with a four year survival of less than 50% in population based studies (fig 1). Ventricular arrhythmias (including non-sustained VT) have been documented in up to 85% of patients with severe congestive heart failure.2 Figure 1  Cumulative survival of 552 incident (new) cases of heart failure identified in the London heart failure studies 1995 to 1998. Kaplan-Meier estimates with 95% point wise confidence bands (authors’ own data). The implantable cardioverter-defibrillator (ICD) is highly effective at terminating life threatening ventricular tachyarrhythmia (fig 2). In selected high risk patients ICDs have proven to be a cost effective method of reducing mortality. At present, 1–2% of the population has heart failure and numbers continue to increase,3 but the ICD remains expensive. The challenge lies in identifying patients with heart failure who are at significant risk of arrhythmia and who would benefit from an ICD in addition to other antiarrhythmic strategies. Figure 2  Implantable cardioverter-defibrillator (ICD) data showing an episode of ventricular fibrillation terminated by a 21 J shock delivered by the device. Intracardiac electrograms are recorded from the right atrium (A) and right ventricle (V) along with a surface ECG. Sensed intracardiac intervals are shown at the bottom of the figure. Following cardioversion, ventricular fibrillation is terminated and bradycardia is seen requiring atrioventricular …

[1]  R. Maestri,et al.  Short-Term Heart Rate Variability Strongly Predicts Sudden Cardiac Death in Chronic Heart Failure Patients , 2003, Circulation.

[2]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[3]  K. Lee,et al.  Prediction of Long-Term Outcomes by Signal-Averaged Electrocardiography in Patients With Unsustained Ventricular Tachycardia, Coronary Artery Disease, and Left Ventricular Dysfunction , 2001, Circulation.

[4]  M. Yokoyama,et al.  Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[5]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[6]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[7]  J. Bigger,et al.  Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. , 1997, The New England journal of medicine.

[8]  E. Caref,et al.  Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and the signal-averaged electrocardiogram. , 1994, Journal of the American College of Cardiology.

[9]  Fesc,et al.  Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. , 1997, Journal of the American College of Cardiology.

[10]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[11]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[12]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[13]  Panos Vardas,et al.  Update of the guidelines on sudden cardiac death of the European Society of Cardiology. , 2003, European heart journal.

[14]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[15]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[16]  S. Hohnloser,et al.  Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era. , 1999, Journal of the American College of Cardiology.

[17]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[18]  J. Mason,et al.  Sudden death in idiopathic dilated cardiomyopathy. , 1987, Annals of internal medicine.

[19]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[20]  M. Nieminen,et al.  Clinical applications of B-type natriuretic peptide (BNP) testing. , 2003, European heart journal.

[21]  K. Kuck,et al.  Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.

[22]  K. Lee,et al.  Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. , 2000, The New England journal of medicine.

[23]  R. Berger,et al.  B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002, Circulation.

[24]  M. Anastasiou-Nana,et al.  Relation of dispersion of QRS and QT in patients with advanced congestive heart failure to cardiac and sudden death mortality. , 2000, The American journal of cardiology.

[25]  K. Bailey,et al.  Failure of signal-averaged electrocardiography with use of time-domain variables to predict inducible ventricular tachycardia in patients with conduction defects. , 1995, Mayo Clinic proceedings.

[26]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[27]  M. Malik,et al.  QT Dispersion Has No Prognostic Information for Patients With Advanced Congestive Heart Failure and Reduced Left Ventricular Systolic Function , 2001, Circulation.

[28]  S. Dubner,et al.  Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. , 1996, Circulation.

[29]  Bigger Jt,et al.  Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery , 1997 .

[30]  E. Ambrosioni,et al.  Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials , 2002, Current opinion in cardiology.

[31]  M. J. Hurst,et al.  The Heart, Arteries and Veins , 1974 .

[32]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[33]  K. Kuck,et al.  Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.

[34]  A. Adgey,et al.  Initiation of ventricular fibrillation outside hospital in patients with acute ischaemic heart disease. , 1982, British heart journal.

[35]  R Lazzara,et al.  Recording from the body surface of arrhythmogenic ventricular activity during the S-T segment. , 1978, The American journal of cardiology.

[36]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[37]  David O. Martin,et al.  Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. , 2002, JAMA.

[38]  S. Saksena,et al.  Device Use Patterns and Clinical Outcome of Implantable Cardioverter Defibrillator Patients with Moderate and Severe Impairment of Left Ventricular Function , 1993, Pacing and clinical electrophysiology : PACE.

[39]  A. Louis,et al.  Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF‐III, ASCOT, COMPANION, UK‐PACE and T‐wave alternans , 2003, European journal of heart failure.

[40]  F. Morady,et al.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. , 2003, Journal of the American College of Cardiology.

[41]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[42]  W. Grimm,et al.  Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. , 2002, Journal of the American College of Cardiology.

[43]  P. Denes,et al.  Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. The Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators. , 1995, Journal of the American College of Cardiology.

[44]  S. Fisher,et al.  Nonsustained ventricular tachycardia in severe heart failure. , 1997, Circulation.

[45]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[46]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[47]  R. Virmani,et al.  Sudden cardiac death. , 1987, Human pathology.

[48]  G. Fonarow,et al.  Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. , 2000, The American journal of cardiology.

[49]  Milton Packer,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[50]  W. Stevenson,et al.  Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. , 1993, Journal of the American College of Cardiology.

[51]  S. Hohnloser,et al.  Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure , 2000, The Lancet.

[52]  F. Morady,et al.  Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. , 1999, Journal of the American College of Cardiology.

[53]  S. Hohnloser,et al.  T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation , 2003, The Lancet.

[54]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[55]  M. Borggrefe,et al.  QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure , 2003, Heart.